Etomidate in the treatment of Cushing syndrome.

Abstract

Cushing syndrome is a metabolic disease caused by chronic exposure to high levels of glucocorticoids. It can present as an endocrine emergency due to a rapid increase in circulating cortisol leading to increased risk of cardiovascular disease and infection. Etomidate rapidly reduces plasma cortisol levels by inhibiting the action of 11β-hidroxilase. We report the case of a patient with severe hypercortisolaemia accompanied by metabolic and psychiatric disorders in whom administration of etomidate reduced preoperative levels of cortisol.

• Authors: N Vergara Molina, N Ruiz Andrés, N Casas Martín, C Ruano Suárez, I Castelo Korro, A Martínez Ruiz
• Journal: Revista espanola de anestesiologia y reanimacion (Rev Esp Anestesiol Reanim (Engl Ed)) Vol. 70 Issue 8 Pg. 473-476 (Oct 2023) ISSN: 2341-1929 [Electronic] Spain
• PMID: 37678461 (Publication Type: Case Reports)
• Copyright: Copyright © 2023 Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Publicado por Elsevier España, S.L.U. All rights reserved.